Peter Sicinski, MD, PhD

Peter Sicinski, MD, PhD


Contact Information

Office Phone Number





Peter Sicinski, MD, PhD

Dr. Sicinski received his MD and PhD from the Warsaw Medical School in Poland. He spent two years as a visiting scientist at the Medical Research Council in Cambridge, England, before becoming a postdoctoral fellow with Dr. Robert A. Weinberg at Massachusetts Institute of Technology. In 1997, Dr. Sicinski joined the faculty of Harvard and Dana-Farber Cancer Institute, where his research focuses on genes in the cell cycle machinery involved in normal cell development and cancer.



Professor of Genetics, Harvard Medical School

Recent Awards

  • AACR-Gertrude B. Elion Cancer Research Award 2002
  • Abbott Bioresearch Center Award 2002
  • Scholar Leukemia & Lymphoma Society Award, 2003
  • Scholar of the Leukemia & Lymphoma Society 2005
  • Foreign Member, Polish Academy of Sciences 2005


    Cell Cycle Machinery in Development and Cancer

    The cell cycle machinery is the ultimate recipient of oncogenic and mitogenic signals.Our laboratory studies the function of the cell cycle machinery at a molecular, cellular and organismal levels. We generated several knock-out and knock-in mouse strains which allow us to dissect the function of cell cycle proteins in normal development and in cancer formation or progression. We are also developing novel strains of mice that allow proteomic approaches to study the functions of cell cycle proteins (including cell cycle-independent functions) in various tissues of the living animal. The broad goal of these new directions is to combine the techniques of mouse germline manipulation with the new methods of proteome- and genome-wide analyses. We are also focusing on the functioning of the cell cycle machinery in various stem cell compartments.An important direction of our studies is to analyze the molecular functions of cell cycle proteins in human cancers.

    Research Departments


      • Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer. J Clin Invest. 2021 02 15; 131(4). View in: Pubmed

      • Stress-Induced Cyclin C Translocation Regulates Cardiac Mitochondrial Dynamics. J Am Heart Assoc. 2020 04 07; 9(7):e014366. View in: Pubmed

      • A mitotic CDK5-PP4 phospho-signaling cascade primes 53BP1 for DNA repair in G1. Nat Commun. 2019 09 18; 10(1):4252. View in: Pubmed

      • A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Rep. 2017 03 28; 18(13):3167-3177. View in: Pubmed

      • Mammalian E-type cyclins control chromosome pairing, telomere stability and CDK2 localization in male meiosis. PLoS Genet. 2014 Feb; 10(2):e1004165. View in: Pubmed

      • Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res. 2010 Oct 15; 70(20):8149-58. View in: Pubmed

      • Peroxisome proliferator-activated receptor-delta induces cell proliferation by a cyclin E1-dependent mechanism and is up-regulated in thyroid tumors. Cancer Res. 2008 Aug 15; 68(16):6578-86. View in: Pubmed

      • Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells. Oncogene. 2008 Sep 11; 27(40):5288-302. View in: Pubmed

      • Duality of p27Kip1 function in tumorigenesis. Genes Dev. 2007 Jul 15; 21(14):1703-6. View in: Pubmed

      • Cyclins and cdks in development and cancer: a perspective. Oncogene. 2005 Apr 18; 24(17):2909-15. View in: Pubmed

      • Cell cycle in mouse development. Oncogene. 2005 Apr 18; 24(17):2877-98. View in: Pubmed

      • Genetic replacement of cyclin D1 function in mouse development by cyclin D2. Mol Cell Biol. 2005 Feb; 25(3):1081-8. View in: Pubmed

      • Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci U S A. 2001 Nov 06; 98(23):13138-43. View in: Pubmed

      • Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001 Jun 28; 411(6841):1017-21. View in: Pubmed

      • Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad Sci U S A. 2001 Jan 02; 98(1):194-9. View in: Pubmed

      • Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol. 2000 May; 12(5):631-8. View in: Pubmed

      • A developmentally regulated switch directs regenerative growth of Schwann cells through cyclin D1. Neuron. 2000 May; 26(2):405-16. View in: Pubmed

      • Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem. 2000 Feb 04; 275(5):3479-84. View in: Pubmed

      • Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999 Oct 01; 18(19):5321-33. View in: Pubmed

      • Rescue of cyclin D1 deficiency by knockin cyclin E. Cell. 1999 Jun 11; 97(6):767-77. View in: Pubmed

      • Cerebellar histogenesis is disturbed in mice lacking cyclin D2. Development. 1999 May; 126(9):1927-35. View in: Pubmed

      • Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev. 1998 Aug 15; 12(16):2469-74. View in: Pubmed

      • A specific role for cyclin D1 in mammary gland development. J Mammary Gland Biol Neoplasia. 1997 Oct; 2(4):335-42. View in: Pubmed

      • Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature. 1996 Dec 05; 384(6608):470-4. View in: Pubmed

      • Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995 Aug 25; 82(4):621-30. View in: Pubmed

      • Developmental and tissue-specific regulation of mouse dystrophin: the embryonic isoform in muscular dystrophy. Neuromuscul Disord. 1991; 1(2):125-33. View in: Pubmed

      • The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989 Jun 30; 244(4912):1578-80. View in: Pubmed


      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Smith 922A Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Smith 922A Boston, MA 02215
      Get Direction
      42.3374, -71.1082